Ascentage Pharma Group International (AAPG) Liabilities and Shareholders Equity (2023 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Historic Liabilities and Shareholders Equity for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q2 2025 value amounting to $421.1 million.

• Ascentage Pharma Group International's Liabilities and Shareholders Equity changed N/A to $421.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.1 billion, marking a year-over-year change of. This contributed to the annual value of $364.4 million for FY2024, which is 300.41% up from last year.
• According to the latest figures from Q2 2025, Ascentage Pharma Group International's Liabilities and Shareholders Equity is $421.1 million.
• In the past 5 years, Ascentage Pharma Group International's Liabilities and Shareholders Equity ranged from a high of $421.1 million in Q2 2025 and a low of $347.3 million during Q4 2023
• In the last 3 years, Ascentage Pharma Group International's Liabilities and Shareholders Equity had a median value of $364.4 million in 2024 and averaged $377.6 million.
• The largest annual percentage gain for Ascentage Pharma Group International's Liabilities and Shareholders Equity in the last 5 years was 494.34% (2024), contrasted with its biggest fall of 494.34% (2024).
• Ascentage Pharma Group International's Liabilities and Shareholders Equity (Quarter) stood at $347.3 million in 2023, then grew by 4.94% to $364.4 million in 2024, then grew by 15.56% to $421.1 million in 2025.
• Its Liabilities and Shareholders Equity stands at $421.1 million for Q2 2025, versus $364.4 million for Q4 2024 and $347.3 million for Q4 2023.

Peer Comparison